Clinical Trial Update: Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating long-term safety, tolerability, and efficacy of APL-130277 for acute treatment of OFF episodes in Parkinson's disease comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• APL-130277 (APL-130277)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-11-22